Morgan Stanley Cuts Ardent Health Partners (NYSE:ARDT) Price Target to $22.00

Ardent Health Partners (NYSE:ARDT) had its price objective lowered by Morgan Stanley from $23.50 to $22.00 in a research report report published on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

ARDT has been the topic of several other reports. Truist Financial cut their price objective on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Leerink Partners lifted their target price on Ardent Health Partners from $23.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 12th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $20.00 target price on shares of Ardent Health Partners in a research report on Tuesday, December 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $23.00 target price on shares of Ardent Health Partners in a research report on Thursday, November 14th. Finally, KeyCorp started coverage on Ardent Health Partners in a research report on Friday, October 11th. They set an “overweight” rating and a $24.00 target price on the stock. Two analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.55.

Ardent Health Partners Price Performance

NYSE:ARDT opened at $15.27 on Tuesday. The firm has a 50-day moving average of $16.11. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.78 and a current ratio of 1.91. Ardent Health Partners has a 12 month low of $13.63 and a 12 month high of $20.72.

Ardent Health Partners (NYSE:ARDT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.10). The business had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.46 billion. As a group, equities research analysts predict that Ardent Health Partners will post 1.22 EPS for the current year.

Hedge Funds Weigh In On Ardent Health Partners

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP bought a new position in shares of Ardent Health Partners in the third quarter valued at $28,724,000. Point72 Asset Management L.P. acquired a new position in Ardent Health Partners during the 3rd quarter worth $27,428,000. Goldentree Asset Management LP acquired a new position in Ardent Health Partners during the 3rd quarter worth $22,897,000. Franklin Resources Inc. acquired a new position in shares of Ardent Health Partners during the third quarter valued at about $15,839,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in Ardent Health Partners in the third quarter worth about $13,119,000.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.